CLAUDIA ORTIZ: Open Payments
NPI 1912570391 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,672 in 107 payments from 24 companies in 2025. Trend: 2023 $1,039 · 2024 $1,870 · 2025 $2,672
Food & beverage: $2,672
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 12 | $369 |
| AstraZeneca Pharmaceuticals LP | 12 | $354 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $338 |
| Lilly USA, LLC | 6 | $230 |
| Verona Pharma, Inc. | 6 | $174 |
| Amgen Inc. | 17 | $166 |
| GlaxoSmithKline, LLC. | 13 | $165 |
| Novo Nordisk Inc | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $88 |
| United Therapeutics Corporation | 3 | $79 |
Products named: DUPIXENT, TEZSPIRE, Ohtuvayre, OFEV, TRELEGY ELLIPTA, MOUNJARO, AIRSUPRA, Ozempic.
Industry payments across CA — which companies pay providers there.
